Kounnas M Z, Chappell D A, Wong H, Argraves W S, Strickland D K
Holland Laboratory, Department of Biochemistry, American Red Cross, Rockville, Maryland 20855, USA.
J Biol Chem. 1995 Apr 21;270(16):9307-12. doi: 10.1074/jbc.270.16.9307.
Hepatic lipase (HL) and lipoprotein lipase (LpL) are structurally related lipolytic enzymes that have distinct functions in lipoprotein catabolism. In addition to its lipolytic activity, LpL binds to very low density lipoproteins and promotes their interaction with the low density lipoprotein receptor-related protein (LRP) (Chappell, D. A., Fry, G. L., Waknitz, M. A., Muhonen, L. E., Pladet M. W., Iverius, P. H., and Strickland, D. K. (1993) J. Biol. Chem. 268, 14168-14175). In vitro binding assays revealed that HL also binds to purified LRP with a KD of 52 nM. Its binding to LRP is inhibited by the 39-kDa receptor-associated protein (RAP), a known LRP antagonist, and by heparin. 125I-Labeled HL is rapidly internalized and degraded by HepG2 cell lines, and approximately 70% of the cellular internalization and degradation is blocked by either exogenously added RAP or anti-LRP IgG. Mouse fibroblasts that lack LRP display a greatly diminished capacity to internalize and degrade HL when compared to control fibroblasts. These data indicate that LRP-mediated cellular uptake of HL accounts for a substantial portion of the internalization of this molecule. Proteoglycans have been shown to participate in the clearance of LpL, and consequently a role for proteoglycans in HL clearance pathway was also investigated. Chinese hamster ovary cell lines that are deficient in proteoglycan biosynthesis were unable to internalize or degrade 125I-HL despite the fact that these cells express LRP. Thus, the initial binding of HL to cell surface proteoglycans is an obligatory step for the delivery of the enzyme to LRP for endocytosis. A small, but significant, amount of 125I-HL was internalized in LRP deficient cells indicating that an LRP-independent pathway for HL internalization does exist. This pathway could involve cell surface proteoglycans, the LDL receptor, or some other unidentified surface protein.
肝脂肪酶(HL)和脂蛋白脂肪酶(LpL)是结构相关的脂解酶,在脂蛋白分解代谢中具有不同的功能。除了其脂解活性外,LpL还与极低密度脂蛋白结合,并促进它们与低密度脂蛋白受体相关蛋白(LRP)的相互作用(查佩尔,D.A.,弗莱,G.L.,瓦克尼茨,M.A.,穆霍嫩,L.E.,普拉德特M.W.,伊维里厄斯,P.H.,和斯特里克兰,D.K.(1993年)《生物化学杂志》268卷,14168 - 14175页)。体外结合试验表明,HL也能以52 nM的解离常数(KD)与纯化的LRP结合。其与LRP的结合受到39 kDa的受体相关蛋白(RAP,一种已知的LRP拮抗剂)和肝素的抑制。125I标记的HL被HepG2细胞系快速内化和降解,并且约70%的细胞内化和降解被外源添加的RAP或抗LRP IgG阻断。与对照成纤维细胞相比,缺乏LRP的小鼠成纤维细胞内化和降解HL的能力大大降低。这些数据表明,LRP介导的HL细胞摄取占该分子内化的很大一部分。蛋白聚糖已被证明参与LpL的清除,因此也研究了蛋白聚糖在HL清除途径中的作用。尽管这些细胞表达LRP,但缺乏蛋白聚糖生物合成的中国仓鼠卵巢细胞系无法内化或降解125I - HL。因此,HL与细胞表面蛋白聚糖的初始结合是该酶传递至LRP进行内吞作用的必要步骤。少量但显著量的125I - HL在缺乏LRP的细胞中被内化,表明确实存在一条不依赖LRP的HL内化途径。该途径可能涉及细胞表面蛋白聚糖、低密度脂蛋白受体或其他一些未鉴定的表面蛋白。